CD34 and Schnyder corneal dystrophy: Another iteration of ABE with high activity (ABE8e) was used to correct a SCD pathogenic mutation in the beta-globin gene HBB in patient CD34+ cells transplanted into humanized mice, with 68% efficiency (Table 1), minimal bystander edits, and a few off-target mutations of no anticipated clinical relevance [68].